SLRX
Salarius Pharmaceuticals, Inc.
Biotechnology
Market Cap$698K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SLRX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+1.3%
SLRX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SLRX | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $698K | $5.83B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-5M | $-464M |
| Total Debt | $222K | $98K |
| Cash & Equiv. | $2M | $714M |
SLRX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SLRX
IMVT
| Stock | May 20 | Feb 26 | Return |
|---|---|---|---|
| Salarius Pharmaceut… (SLRX) | 100 | 0.0 | -100.0% |
| Immunovant, Inc. (IMVT) | 100 | 101.3 | +1.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLRX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SLRX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Immunovant, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SLRX
Salarius Pharmaceuticals, Inc.
The Income Pick
SLRX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.10
- Lower volatility, beta 1.10, Low D/E 14.7%, current ratio 1.98x
- Beta 1.10, current ratio 1.98x
Best for: income & stability and sleep-well-at-night
IMVT
Immunovant, Inc.
The Growth Play
IMVT is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -45.2%
- 188.1% 10Y total return vs SLRX's -100.0%
- +107.2% vs SLRX's -93.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLRX | -0.2% revenue growth vs IMVT's -21.3% |
| Quality / Margins | SLRX | 5.2% margin vs IMVT's 3.2% |
| Stability / Safety | SLRX | Beta 1.10 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +107.2% vs SLRX's -93.3% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs SLRX's -82.1% |
SLRX vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2020
Segment breakdown not available.
SLRX vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGSLRX
SLRXSalarius Pharmaceutic…
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs SLRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SLRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SLRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SLRX and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SLRXSalarius Pharmace… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$5M | -$487M |
| Net IncomeAfter-tax profit | -$5M | -$464M |
| Free Cash FlowCash after capex | -$4M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +84.1% | +19.7% |
SLRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SLRX and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SLRXSalarius Pharmace… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $697,790 | $5.8B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.03x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SLRX and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-118 for SLRX. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SLRX's 0.15x. On the Piotroski fundamental quality scale (0–9), SLRX scores 3/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | SLRXSalarius Pharmace… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -117.8% | -47.1% |
| ROA (TTM)Return on assets | -82.1% | -44.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -168.7% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.15x | 0.00x |
| Net DebtTotal debt minus cash | -$2M | -$714M |
| Cash & Equiv.Liquid assets | $2M | $714M |
| Total DebtShort + long-term debt | $221,866 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
IMVT leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $2 for SLRX. Over the past 12 months, IMVT leads with a +107.2% total return vs SLRX's -93.3%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs SLRX's -85.8% — a key indicator of consistent wealth creation.
| Metric | SLRXSalarius Pharmace… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +13.3% | +10.7% |
| 1-Year ReturnPast 12 months | -93.3% | +107.2% |
| 3-Year ReturnCumulative with dividends | -99.7% | +48.4% |
| 5-Year ReturnCumulative with dividends | -100.0% | +73.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -85.8% | +14.1% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SLRX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
SLRX is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 95.3% from its 52-week high vs SLRX's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLRXSalarius Pharmace… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.37x |
| 52-Week HighHighest price in past year | $34.65 | $30.09 |
| 52-Week LowLowest price in past year | $0.52 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +2.1% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 47.6 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 79K | 1.4M |
Evenly matched — SLRX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SLRXSalarius Pharmace… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $45.50 |
| # AnalystsCovering analysts | — | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). SLRX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
SLRX vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SLRX or IMVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SLRX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SLRX or IMVT?
By beta (market sensitivity over 5 years), Salarius Pharmaceuticals, Inc.
(SLRX) is the lower-risk stock at 1. 10β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 25% more volatile than SLRX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 15% for Salarius Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SLRX or IMVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -45. 2% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SLRX or IMVT?
Salarius Pharmaceuticals, Inc.
(SLRX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLRX leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — SLRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SLRX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SLRX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Salarius Pharmaceuticals, Inc.
(SLRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Both have compounded well over 10 years (SLRX: -100. 0%, IMVT: +188. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SLRX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.